🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wang et al. performed multidimensional analysis on longitudinal tumor and blood samples in a clinical trial of TIL therapy in 16 patients with metastatic NSCLC. bit.ly/43rBspk  Ben Creelan, MD  Moffitt Cancer Center

Weathers et al. reported that the concurrent use of atezolizumab in combination with radiation and TMZ was safe, and demonstrated efficacy consistent with published trials for newly diagnosed GBM. bit.ly/3GZBXj5  @Mdandersonews

Schulte, Peter, and Rosenberger et al. evaluated IDH-mutant and wild-type gliomas for mutations in 16 genes encoding proteins involved in antigen presentation (HLAs and HLA-related proteins) using a bioinformatics pipeline [...] bit.ly/4k8LcvX  Heinrich-Heine-Universität Düsseldorf  Malte Mohme

Zhu et al. demonstrated a coordinated interplay between innate and adaptive immunity during the initiation and progression of LUAD pre-cancers, revealing stage-specific remodeling of the tumor microenvironment [...] bit.ly/4k6ilrW @Mdandersonews

🔎 Making targeting the obvious more obvious - identification of physiologic ALK-targeting CD4 cells bit.ly/4dW6eM9

🎯 A healthy approach to targeting KRAS - NeoStim from healthy donors identifies a plethora of mutant KRAS-targeting TCRs bit.ly/4dC7409

⚖️ Not all DCs are created equal: Brain tumors induce suppressive DCs in the draining lymph nodes bit.ly/4kCb038

🚨 We’re proud to be a media partner for #CIMT2025! 🚨 Our full coverage of the meeting is now live so dive in here: bit.ly/3SUQCOX. Staying up to date with cutting-edge scientific research isn’t just important, it’s essential. #immunotherapy

👀 Look this way before you leap - SCRNASeq of PBMC reveals markers which predict IO response bit.ly/4mBtoLq

2️⃣ Will two be better than one?: Real-word evidence for a bispecific targeting CTLA-4 and PD-1 bit.ly/3SsdyFc

To enhance CAR performance, Susana Minguet has turned to the structure of the native TCR signaling complex. Read more about her science here 👉 bit.ly/3SUQCOX.

To everyone working toward a cure: thank you. 💙 Your dedication — in labs, in clinics, and in staying sharp with the latest research — is changing lives. Science moves fast. Staying informed keeps us all in the fight. #CancerResearch #ScienceMatters

⭕ Sounds circular but it works: Using approved, off-the-shelf vaccines to stimulate in situ vaccination bit.ly/3Ftx8Oq

Most tumor antigens derive from the unmutated genome. Read our digest 👉 bit.ly/3T6a4bA  IRIC

Saxena, Anker, Kodysh et al. demonstrated that the personalized long-peptide neoantigen vaccine PGV001, in combination with atezolizumab, was feasible, safe, and elicited durable neoantigen-specific T cell [...] bit.ly/3T6h5cq  Icahn School of Medicine at Mount Sinai  Julia Kodysh  Matt Galsky

Schiele, Japp, Stark et al. showed that up to half of tumor-specific CD8+ T cells in mice bearing CD40-expressing cancers were CD40L+. CD40L-/-CD8+ T cells transferred into RAG1-/- mice failed to reject CD40+ tumor cells, even when [...] bit.ly/4kqmnLV

Blanchard and Vina et al. investigated mechanisms by which anti-CTLA-4 mAbs modulate tumor-associated high endothelial venules (TA-HEVs), which are important for supporting lymphocyte entry into tumors. bit.ly/4dNZyzu  Lucas Blanchard

To identify novel neoantigens, Cai et al. assembled an immunopeptidomics atlas from published tumor and normal tissue datasets. bit.ly/3SANUOI